Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Oct 10, 2025
Tickeron AI Trading Bots Deliver Up to 82% Annualized Gains Amid Market Volatility

Tickeron AI Trading Bots Deliver Up to 82% Annualized Gains Amid Market Volatility

SAN FRANCISCO, Oct. 6, 2025 /PRNewswire/ — Tickeron, a pioneer in AI-driven trading solutions, today highlighted the exceptional performance of its advanced AI Trading Bots, delivering annualized returns as high as 82% amid surging global markets. As U.S. stock futures climb— with Dow Jones futures up 0.2%, S&P 500 futures gaining 0.3%, and Nasdaq-100 contracts rising 0.4%—driven by AMD’s multi-billion-dollar deal with OpenAI and Tesla’s pre-event buzz, Tickeron’s bots continue to outperform, adapting swiftly to intraday volatility and government shutdown uncertainties.

AI Trading for Stock Market | Tickeron

Revolutionizing AI Trading with Shorter Machine Learning Intervals

Tickeron has unveiled a groundbreaking upgrade to its AI Trading Agents, now operating on ultra-responsive 5-minute and 15-minute Machine Learning (ML) time frames, a leap from the traditional 60-minute standard. This innovation, powered by enhanced proprietary Financial Learning Models (FLMs), enables real-time analysis of price action, volume spikes, news sentiment, and macroeconomic shifts. Early backtests and forward-testing across 500+ scenarios show a 25% improvement in trade timing accuracy, reducing drawdowns by 18% during high-volatility periods like today’s Asian market surges, where Japan’s Nikkei hit all-time highs amid yen weakness.

By scaling its AI infrastructure, Tickeron processes over 1 million data points per minute, allowing bots to detect subtle patterns—such as the 5% Nikkei rally triggered by fiscal policy doves—that human traders might miss. This positions Tickeron’s tools as essential for navigating the current bull run, with U.S. indices on track for seven straight winning weeks despite ongoing fiscal drags.

Stellar Trading Results from AI Bots

Tickeron’s AI Trading Bots have posted remarkable gains in live and simulated environments, underscoring their edge in today’s dynamic landscape. The flagship AI Trading Agent on a 5-minute interval delivered an impressive +82% annualized return over 90 days, generating $16,224 in closed trades profit/loss (P/L) from an initial $100,000 balance with $10,000 per trade. Complementing this, the multi-ticker AI Trading Agent (covering AAPL, GOOG, NVDA, TSLA, MSFT, SOXL, SOXS, QID, and QLD) on a 60-minute frame achieved +72% annualized returns across 125 days, yielding $20,711 in P/L.

For focused strategies, the AI Trading Double Agent on MRVL and SOXS, using 15-minute intervals, secured +69% annualized returns in just 46 days, with $6,529 P/L. Aggregated stats reveal over 1,200 closed trades with a 68% win rate, average holding time under 45 minutes, and a Sharpe ratio of 2.1—far surpassing benchmarks like the S&P 500’s 1.2. These results, validated on Tickeron.com, highlight how shorter ML cycles capture opportunities like AMD’s 12% premarket soar on OpenAI news.

Additional portfolio simulations show diversified bots outperforming single-asset strategies by 15%, with risk-adjusted returns climbing 22% in backtests spanning 2024-2025 volatility. Traders using these bots reported 35% higher consistency during events like last week’s record rally.

Navigating Today’s Market Momentum with Precision

In a week where Wall Street eyes continued highs—bolstered by Tesla’s 3% premarket gain ahead of its October 8 event and broader tech optimism—Tickeron’s bots excel at parsing noise from signal. With Asia-Pacific markets mixed yet upbeat and U.S. futures signaling another up day amid shutdown talks, the bots’ FLMs have flagged bullish patterns in 78% of monitored tickers, including NVDA and TSLA, aligning with intraday swings up to 4%. This adaptability ensures users capitalize on momentum without emotional bias, as evidenced by a 28% P/L uplift in simulated trades during similar fiscal uncertainty in Q3 2025.

Spotlight on Tickeron’s AI Agents: The Future of Autonomous Trading

Tickeron’s AI Agents represent the pinnacle of autonomous trading intelligence, blending signal generation, virtual portfolio management, and real-money execution into seamless workflows. Available via Tickeron’s AI Agents page, these agents—spanning Signal Agents for buy/sell alerts, Virtual Agents for simulated strategies, and Brokerage Agents for live trades—leverage FLMs to mimic institutional desks. With over 50 pre-built agents scanning 10,000+ assets daily, they deliver 92% pattern recognition accuracy, enabling users to follow high-performers like the 82% return bot effortlessly. As CEO Sergey Savastiouk, Ph.D., notes, “Our agents aren’t just tools; they’re adaptive partners in an unpredictable market,” empowering retail investors with pro-level execution at Tickeron.com/bot-trading/.

Exploring Tickeron’s Comprehensive Product Suite

Tickeron’s ecosystem extends beyond bots to a full arsenal of AI-powered tools, democratizing advanced analytics for all investors. The AI Trend Prediction Engine forecasts directional moves with 85% historical accuracy across equities and ETFs. Complementing it, the AI Patterns Search Engine and AI Real-Time Patterns Scanner identify emerging setups in seconds, scanning millions of charts for breakouts like today’s AMD surge.

For deeper insights, the AI Screener filters thousands of stocks by 200+ criteria, while its Time Machine backtests strategies across decades—revealing, for instance, how NVDA-like patterns yielded 150% returns in past bull phases. Topping it off, Daily Buy/Sell Signals provide actionable alerts for 1,000+ tickers, with users reporting 40% improved hit rates. Explore copy-trading options at Tickeron.com/copy-trading/ or dive into AI stock trading at Tickeron.com/ai-stock-trading/, alongside virtual agents at Tickeron.com/bot-trading/virtualagents/all/, signals at Tickeron.com/bot-trading/signals/all/, and real-money bots at Tickeron.com/bot-trading/realmoney/all/.

Exclusive Fall Sale: Unlock AI Power at 50-70% Off

Seize the last days of Tickeron’s Fall Sale, offering up to 70% off annual subscriptions to supercharge your trading. Daily Buy/Sell Signals—featuring all-ticker analytics, articles, videos, and portfolios—drops from $200/year to just $60/year ($5/month), a 70% savings exclusive to this promo. For advanced users, AI Robots (Signal, Virtual, and Brokerage Agents on 60-minute ML) slash from $1,000/year to $540/year ($45/month), while AI Robots Unlimited (adding 15- and 5-minute frames) falls from $3,000/year to $1,500/year ($125/month)—both at 50% off. Visit Tickeron.com to subscribe and follow updates on Twitter @Tickeron. Limited time—act now to harness 82% return potential.

About Tickeron

Tickeron is a financial technology company specializing in AI-driven trading and investing tools. Powered by proprietary Financial Learning Models (FLMs), Tickeron delivers real-time data analysis, pattern recognition, and predictive analytics for individual and institutional investors. Much like large language models process text for contextual insights, Tickeron’s FLMs ingest vast market datasets to generate adaptive strategies, ensuring users stay ahead in volatile environments. For more, visit www.tickeron.com.

Disclaimers and Limitations

Related Ticker: UGL, AAPL, MRVL, SOXS

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


UGL in downward trend: price dove below 50-day moving average on September 23, 2026

UGL moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for UGL moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 37 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UGL as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for UGL turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 37 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

UGL broke above its upper Bollinger Band on August 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for UGL entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 54 cases where UGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +4.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where UGL advanced for three days, in 289 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold SubindexSM. The fund seeks to meet its investment objective by investing, under normal market conditions, in any one of, or combinations of, Financial Instruments (including swap agreements, futures contracts, forward contracts and option contracts) based on the benchmark. The types and mix of Financial Instruments in which the fund invests may vary daily at the discretion of the Sponsor. It will not invest directly in any commodity.
View a ticker or compare two or three
UGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Commodities
Address
ProShares Trust II7501 WISCONSIN AVEBethesda
Phone
240-497-6400
Web
www.proshares.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.